Want to see GB:ABDX full AI Analyst Report?
ABDX Stock Chart & Stats
11.00 p
0.10 p(1.03%)
At close: 4:00 PM EDT
11.00 p
0.10 p(1.03%)
Day’s Range― - ―
52-Week Range5.50 p - 13.00 p
Previous CloseN/A
Volume87.84K
Average Volume (3M)119.61K
Market Cap
£22.75M
Enterprise Value43.07M
Total Cash (Recent Filing)£2.87M
Total Debt (Recent Filing)£1.34M
Price to Earnings (P/E)―
Beta-0.25
Next Earnings
Mar 31, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding252,751,500
10 Day Avg. Volume168,108
30 Day Avg. Volume119,608
Financial Highlights & Ratios
PEG Ratio0.45
Price to Book (P/B)6.96
Price to Sales (P/S)3.86
P/FCF Ratio-23.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)<0.01
Revenue Forecast (FY)£14.30M
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthRapid organic revenue expansion demonstrates growing demand for the company’s diagnostic development and manufacturing services. Continued growth at this scale can improve operating leverage, support investment in capabilities, and strengthen Abingdon’s position with customers seeking broader diagnostic support.
Improving Margins And Operating LeverageThe move to positive adjusted EBITDA in the second half, alongside higher gross margin, indicates that existing infrastructure can support better profitability as revenue scales. If sustained, this operating leverage should improve earnings quality and reduce the gap between growth and cash generation.
Larger, Longer-Dated Customer ProgramsMulti-year programs can make revenue less dependent on individual short-term projects and deepen customer relationships across development, regulatory, testing, and manufacturing. Greater visibility also supports capacity planning and gives the company a stronger platform for converting its pipeline into recurring activity.
Bears Say
Persistent Losses And Cash BurnThe company remains unable to fund operations internally, despite substantial revenue growth and improved second-half EBITDA. Continued losses and negative operating cash flow can constrain investment, increase reliance on external financing, and delay the point at which growth translates into durable shareholder value.
Program Delays Shift Revenue LaterDelays caused by unavailable customer reagents and specification changes can defer revenue recognition and make quarterly performance less predictable. A heavier second-half revenue concentration increases execution pressure and leaves less time to recover if customer programs encounter further technical or operational setbacks.
Manufacturing Conversion Still DevelopingFlat contract manufacturing revenue shows that the current growth base has not yet translated broadly into higher production volumes. Until more development programs complete approval and enter manufacturing, the company may capture less recurring commercial value and remain exposed to project timing and conversion risk.
Abingdon Health PLC News
ABDX FAQ
What was Abingdon Health PLC’s price range in the past 12 months?
Abingdon Health PLC lowest share price was 5.50 p and its highest was 13.00 p in the past 12 months.
What is Abingdon Health PLC’s market cap?
Abingdon Health PLC’s market cap is £22.75M.
When is Abingdon Health PLC’s upcoming earnings report date?
Abingdon Health PLC’s upcoming earnings report date is Mar 31, 2027 which is in 159 days.
How were Abingdon Health PLC’s earnings last quarter?
Abingdon Health PLC released its earnings results on Oct 13, 2026. The company reported 0 p earnings per share for the quarter, missing the consensus estimate of 0.001 p by -0.001 p.
Is Abingdon Health PLC overvalued?
According to Wall Street analysts Abingdon Health PLC’s price is currently Overvalued.
Does Abingdon Health PLC pay dividends?
Abingdon Health PLC does not currently pay dividends.
What is Abingdon Health PLC’s EPS estimate?
Abingdon Health PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Abingdon Health PLC have?
Abingdon Health PLC has 252,751,500 shares outstanding.
What happened to Abingdon Health PLC’s price movement after its last earnings report?
Abingdon Health PLC reported an EPS of 0 p in its last earnings report, missing expectations of 0.001 p. Following the earnings report the stock price went down -11.628%.
Which hedge fund is a major shareholder of Abingdon Health PLC?
Currently, no hedge funds are holding shares in GB:ABDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Abingdon Health PLC
Established in 2008 and based in York, United Kingdom, Abingdon Health Plc is a global entity dedicated to the creation, production, and worldwide distribution of diagnostic instruments. Their product line features the AbC-19 Rapid Test, a fast-acting diagnostic for COVID-19 IgG antibodies, alongside various nucleic acid lateral flow immunoassays. They also offer Seralite, a swift lateral flow test for accurately measuring kappa and lambda immunoglobulin free light chains in blood serum. Additionally, their AppDx technology converts any smartphone into an autonomous and adaptable lateral-flow reader. Beyond these offerings, the company provides expert services in lateral flow development and manufacturing, as well as advisory support to firms in the health tech industry. Abingdon Health Plc also engages in a collaborative and co-marketing partnership with Abcam plc.
Technical Analysis
Circassia Pharmaceuticals
―
EKF Diagnostics Holdings
―
Genedrive
―
Omega Diagnostics
―
Renalytix
―